This brand name is authorized in United States. It is also authorized in Israel.
The drug UBRELVY contains one active pharmaceutical ingredient (API):
1
|
Ubrogepant
UNII
AD0O8X2QJR - UBROGEPANT
|
|
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is used for the acute treatment of migraine with or without aura in adults. |
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| UBRELVY Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| IL | מִשְׂרַד הַבְּרִיאוּת | 9114, 9115 |
| US | FDA, National Drug Code | 0023-6498, 0023-6501 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.